Cardinal Health, Inc. (BVMF:C1AH34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 286.20B +51.9% |
| Revenue (ttm) | 1.32T +14.2% |
| Net Income | 8.88B +9.8% |
| EPS | 37.46 +12.1% |
| Shares Out | n/a |
| PE Ratio | 32.23 |
| Forward PE | 18.78 |
| Dividend | 6.93 (0.58%) |
| Ex-Dividend Date | Jun 30, 2026 |
| Volume | 10 |
| Open | 1,226.40 |
| Previous Close | 1,199.26 |
| Day's Range | 1,226.40 - 1,226.40 |
| 52-Week Range | 814.72 - 1,272.00 |
| Beta | 0.52 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About Cardinal Health
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products.... [Read more]
Financial Performance
In fiscal year 2026, Cardinal Health's revenue was $254.25 billion, an increase of 14.23% compared to the previous year's $222.58 billion. Earnings were $1.71 billion, an increase of 9.80%.
Financial numbers in USD Financial StatementsNews
Cardinal Health price target raised to $292 from $275 at Leerink
Leerink raised the firm’s price target on Cardinal Health (CAH) to $292 from $275 and keeps an Outperform rating on the shares.
Cardinal Health Earnings Call Transcript: Q4 2026
Q4 and fiscal 2026 saw strong revenue, profit, and cash flow growth, led by Pharmaceutical and Specialty Solutions and other growth businesses. Fiscal 2027 guidance calls for double-digit EPS and profit growth, continued investment, and robust capital returns, with risks from tariffs, input costs, and regulatory changes.
Cardinal Health Earnings release: Q4 2026
Cardinal Health released its Q4 2026 earnings on August 11, 2026, summarizing the period's financial results.
Cardinal Health Slides: Q4 2026
Cardinal Health has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on August 11, 2026.
Cardinal Health Annual report: Q4 2026
Cardinal Health has published its Q4 2026 annual report on August 11, 2026.
Cardinal Health forecasts full-year profit above estimates on specialty drug strength
U.S. drug distributor Cardinal Health on Tuesday forecast fiscal 2027 profit well above Wall Street expectations after topping fourth-quarter profit estimates, driven by sustained demand for special...
Can Cardinal Health's Strong Earnings Guidance Offset a Mixed Quarter?
Cardinal Health reports mixed quarterly performance across its business segments as earnings get a lift from one-time tariff refunds.
Cardinal Health Logs Mixed Sales, Sees Growth in New Year
Cardinal Health had a mixed fiscal fourth quarter in terms of sales across its two main business lines, but expects revenue to rise in both segments in the new fiscal year.
Cardinal Health reports Q4 ex-items EPS $2.60, consensus $2.42
Reports Q4 revenue $63.67B, consensus $65.11B. “Fiscal 2026 was a standout year for Cardinal Health (CAH) and I am pleased with our strong fourth quarter results,” said Jason Hollar, CEO…
Cardinal Health sees FY27 EPS $12.40-$12.60, consensus $12.05
The company said, “Financial guidance for fiscal year 2027 reflects the estimated impact of the Company’s recently completed tuck-in acquisition of Strive Medical and the announced tuck-in acquisition...
Cardinal Health Reports Fourth Quarter and Fiscal Year 2026 Results and Provides Fiscal Year 2027 Guidance
Fourth quarter revenue increased 6% to $63.7 billion Fourth quarter GAAP 1 diluted EPS increased 70% to $1.70 Excluding a one-time positive impact of $0.31 from the recognition of the IEEPA tariff ref...
Cardinal Health Board of Directors Approves Quarterly Dividend
DUBLIN, Ohio,, Aug. 11, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5158 per share, out of the Company's capital ...
Cardinal Health price target raised to $265 from $245 at Citi
Citi raised the firm’s price target on Cardinal Health (CAH) to $265 from $245 and keeps a Buy rating on the shares.
Cardinal Health price target raised to $240 from $235 at Mizuho
Mizuho analyst Steven Valiquette raised the firm’s price target on Cardinal Health (CAH) to $240 from $235 and keeps an Outperform rating on the shares. The firm upped the company’s…
Cardinal Health to buy AdaptHealth diabetes unit, Strive Medical for $360 million
Cardinal Health said on Monday it has agreed to buy AdaptHealth's diabetes health business and medical supply provider Strive Medical in separate deals for about $360 million in total, expanding its...
Cardinal to acquire Diabetes business of AdaptHealth, Strive Medical for $360M
Cardinal Health (CAH) announced it has entered into two definitive agreements. Cardinal Health will acquire the Diabetes Health business of AdaptHealth (AHCO), and, in its entirety, Strive Medical, a ...
Cardinal Health expands home care business with two tuck-in acquisitions
DUBLIN, Ohio, July 20, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today it has entered into two definitive agreements that accelerate its at-Home Solutions' growth strategy. Cardinal H...
AdaptHealth to divest diabetes health business to Cardinal Health for $235M
AdaptHealth Corp. (AHCO) that it is divesting its Diabetes Health business to Cardinal Health (CAH). Under the terms of an agreement signed July 19, 2026, Cardinal Health will acquire AdaptHealth’s…
Cardinal Health price target raised to $274 from $260 at UBS
UBS raised the firm’s price target on Cardinal Health (CAH) to $274 from $260 and keeps a Buy rating on the shares.
Cardinal Health price target raised to $275 from $255 at TD Cowen
TD Cowen raised the firm’s price target on Cardinal Health (CAH) to $275 from $255 and keeps a Buy rating on the shares. The firm updated its model ahead of…
Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2026 on August 11
DUBLIN, Ohio, July 9, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2026 on August 11, prior to the opening of tra...
Cardinal Health price target raised to $260 from $240 at BofA
BofA raised the firm’s price target on Cardinal Health (CAH) to $260 from $240 and keeps a Buy rating on the shares, citing relative upside to consensus estimates and strong…
Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026
Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deo...
Cardinal Health Transcript: Bank of America Global Healthcare Conference 2026
Strong Q3 profit growth and raised guidance reflect robust demand and operational execution across all segments. Strategic M&A in GI and urology, investments in innovation, and disciplined capital allocation support long-term growth and resilience.